

Reference FOI202324/325

Number:

From: Private Individual

Date: 17 October 2023

Subject: Electronic prescribing, penicillamine allergies and electroic prescribing

incidents

Q1 Do you currently use an electronic prescribing system?

A1 Yes

Q2 If so, who is the supplier and what version of the software do you use?

A2 Altera Sunrise Version 22.1

Q3 Have you been on the same electronic prescribing system between 01/10/2022 to 01/10/2023?

A3 Yes

- Q4 How many allergies have been added to patient records in the system for the drug penicillamine between 01/10/2022 to 01/10/2023?
- The Trust is unable to respond to all or specific elements of your request where the response would indicate five or less individuals. The Trust is withholding this information under Section 40 (Personal Information) of the Freedom of Information Act (FOIA) 2000 to reduce the risk of any individuals being identified. The Trust is of the view that disclosure of such information would significantly increase the risk of individuals being identified and as such would constitute a breach of their personal data.

The Trust has applied exemption Section 40(2) of the FOIA and is therefore withholding the information as disclosure which may identify an individual would breach their rights under the Data Protection Act 2018. The grounds for application of this exemption include:

- Any data relating to patients or staff is third party data, furthermore health data is classified as sensitive personal data within the Data Protection Act 2018. As such, Section 40 (2) of the FOIA applies along with the Trusts duty of confidentiality. Therefore under s.2 (3) (f) (ii) of the FOIA, there is an absolute exemption from disclosure on the grounds that it would contravene the First Data Protection Principle.
- The Trust has a duty under the Data Protection Act 2018 and specifically the First Data Protection Principle to ensure personal data regarding staff and patients is processed fairly and lawfully. Disclosure of such data which may identify an individual, either through the data alone or other data in conjunction with that data which may identify an individual would therefore breach this principle.
- The Data Protection Act 2018 defines sensitive personal data to include data relating to the "physical or mental health or condition" of a person. Any such information about specific individuals falls within this category and disclosure of such data including



statistical data, with any potential likelihood of identification would breach the Data Protection Act 2018.

- Q5 How many of these penicillamine drug allergies were recorded as anaphylaxis?
- A5 As per A4
- Q6 How many allergies have been added to patient records in the system for the drug class penicillins between 01/10/2022 to 01/10/2023?
- A6 865
- Q7 Do you have any mitigations in place to prevent users adding penicillamine drug allergies to patient records in error?
- A7 No
- Q8 Do you report electronic prescribing system incidents to any governing bodies outside of your Trust? (e.g MHRA Yellow Card)
- A8 Yes. MHRA Yellow cards if applicable. All medicines safety incidents including electronic prescribing system incidents are reported to NHS England Learning from Patient Safety Events (LFPSE) and to the Integrated Care Board (ICB).